Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
出版年份 2016 全文链接
标题
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
作者
关键词
Androgen Receptor, Breast Cancer Resistance Protein, Dextromethorphan, Abiraterone, Enzalutamide
出版物
CLINICAL PHARMACOKINETICS
Volume 55, Issue 11, Pages 1369-1380
出版商
Springer Nature
发表日期
2016-04-22
DOI
10.1007/s40262-016-0403-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
- (2016) Hideyuki Akaza et al. International Journal of Clinical Oncology
- Pharmacokinetic Drug Interaction Studies with Enzalutamide
- (2015) Jacqueline A. Gibbons et al. CLINICAL PHARMACOKINETICS
- Clinical Pharmacokinetic Studies of Enzalutamide
- (2015) Jacqueline A. Gibbons et al. CLINICAL PHARMACOKINETICS
- Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer
- (2015) Kim N. Chi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing
- (2014) Kouichi Inoue et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Naïve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer
- (2014) Kim Stuyckens et al. CLINICAL PHARMACOKINETICS
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment
- (2013) Thomas Marbury et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer
- (2012) K. N. Chi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects
- (2012) Milin Acharya et al. XENOBIOTICA
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More